Physician profile
Charissa N Wright
NPI 1679219620
$959.02
in general payments reported to CMS, 2019-2025
11 companies · $469 in 2025
The $469 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $39.93 · 2023: $234 · 2024: $216 · 2025: $469.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $469 · Food and Beverage: $450.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $469.47 |
| Food and Beverage | $449.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adma Biomanufacturing LLC | $469.47 | 2025 | |
| Sumitomo Pharma America, INC. | $134.85 | 2023-2024 | Myfembree |
| Mayne Pharma Commercial LLC | $119.44 | 2023-2024 | |
| Medtronic, INC. | $92.33 | 2024 | Interstim |
| Exeltis, USA INC. | $33.92 | 2023-2024 | Slynd |
| Hologic Sales and Service, LLC | $21.70 | 2023 | Coolseal Generator |
| Sanofi-Aventis U.S. LLC | $20.11 | 2022 | |
| Amgen INC. | $19.82 | 2022 | |
| Paratek Pharmaceuticals, INC. | $17.14 | 2024 | Nuzyra |
| Astrazeneca Pharmaceuticals Lp | $15.16 | 2024 | Breztri |
| Lilly USA, LLC | $15.08 | 2024 | Mounjaro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charissa Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.